Multiple Serotonin Receptors: Clinical and Experimental Aspects

REFERENCES

• Rapport MM: Serotonin research: Historical overview. In: Paoletti R, Vanhoutte PM, Brunello N, Maggi FM, eds. Se-rotonin: From Cell Biology to Pharmacology and Therapeu-tics. Basel: Kluwer Academic Press; 1990:1–4
   Google Scholar
• Rapport MM, Green AA, Page IH: Crystalline serotonin. Sci-ence 1948; 108:329
   PubMed Web of Science ®Google Scholar
• Wooley DW, Shaw E: A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954; 40: 228–231
   PubMed Web of Science ®Google Scholar
• Gaddum JH, Picarelli ZP: Two kinds of tryptamine receptors. Br J Pharmacol 1957; 12:323–328
   PubMed Web of Science ®Google Scholar
• Gaddum JH, Hameed KA: drugs which antagonize 5-hy-droxytryptamine. Br J Pharmacol 1954; 9:240–248
   PubMed Web of Science ®Google Scholar
• Aghajanian GK, vanderMaelen CP: Specific systems of the reticular core: Serotonin. In: Mountcastle VB, Bloom FE, Geiger SR, eds. Handbook of Physiology—The Nervous System, Vol IV, IV ed. Bethesda, MD: American Physiologi-cal Society; 1986:237–256
   Google Scholar
• Meltzer HY: The significance of serotonin for neuropsychia-tric disorders. J Clin Psychiatry 1991; 52:70–72
   Web of Science ®Google Scholar
• Roth BL, Meltzer HY: The role of serotonin in schizophre-nia. In: Kupfer DJ, Bloom FE, eds., Psychopharmacology: A 4th Generation of Progress (in press)
   Google Scholar
• Meltzer HY, Lowy MT: The serotonin hypothesis of depression. In: Meltzer HY, ed. Psychopharmacology: The Third Genera-tion of Progress. New York: Raven Press; 1987:513–526
   Google Scholar
• Charney DS, Woods SW, Goodman WK, Heninger GK: Se-rotonin function in anxiety. Psychopharmacology 1987; 92:14–24
   PubMed Web of Science ®Google Scholar
• Kaye WH, Weltzin TE: Serotonin activity in anorexia and bulimia nervosa: Relationship to the modulation of feeding and mood. J Clin Psychiatry 1991; 52:41–48
   PubMedGoogle Scholar
• Kakis 0, Kanh RS, Wetzler S, Asnis GM, Van-Praag HM: Hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks. Biol Psychiatry 1990; 28:1053–1057
   Google Scholar
• Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY: Fluoxet-ine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:1064–1067
   PubMed Web of Science ®Google Scholar
• Stanley M, Mann JJ: Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1984; 1:214–216
   Google Scholar
• Cross AJ, Crow TJ, Ferrier IN, Perry EK, Perry RH, Blessed G, Tomlinson BE: Serotonin receptor changes in dementia of the Alzheimer's type. J Neurochem 1984; 43:1574–1581
   PubMedGoogle Scholar
• Bastani B, Nash JF, Meltzer HY: Prolactin and cortisol re-sponse to MK-212, a serotonin agonist, in obsessive-compul-sive disorder. Arch Gen Psychiatry 1990; 47:833–839
   Web of Science ®Google Scholar
• Bradley PB, Engle G, Faniuk W, Fozard JR, Humphrey PPA, Middlemis DN, Lecharane El, Richardson BP, Saxena PR: Proposals for the classification and nomenclature of func-tional receptors of 5-hydroxytryptamine. Neuropharmacology 1986; 25:563–576.
   PubMed Web of Science ®Google Scholar
• Weinberger OR, Berman KF, Illowsky BP: Physiological dys-function of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mecha-nism. Arch Gen Psychiatry 1988; 45:609–615
   PubMed Web of Science ®Google Scholar
• Cooper JR, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology. 6th ed. New York: Oxford; 1991
   Google Scholar
• Pazos A, Palacios JM: Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 recep-tors. Brain Res 1985; 346:231–249
   PubMed Web of Science ®Google Scholar
• Hoyer D: Functional correlates to 5-HT1 recognition sites. J Recept Res 1988; 8:59–81
   PubMed Web of Science ®Google Scholar
• Hoyer D, Middlemiss DN: The pharmacology of the terminal 5-HT autoreceptors in mammalian brain: Evidence for spe-cies differences. Trends Pharm Sci 1989; 10:130–132
   PubMed Web of Science ®Google Scholar
• Doenicke A, Brand J, Perrin VL: Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1988; 1:1309
   PubMedGoogle Scholar
• Bockaert J, Dumuis A, Bouhelal R, Sebben M, Cory RN: Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5-HTIA receptors negatively coupled with adenylate cyclase in hippocampal neurons. Naunyn Arch Schmiedebergs Pharmacol 1987; 335:588–592
   Google Scholar
• Hoffman BJ, Mezey E, Brownstein MJ: Cloning of a sero-tonin transporter affected by antidepressants. Science 1991; 252:579–580
   Google Scholar
• Ricaurte G, Bryan G, Strauss, L, Seiden L, Schuster C: Hal-lucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229:986–988
   PubMed Web of Science ®Google Scholar
• Schmidt CJ, Wu L, Lovenberg W: Methylenedioxyam-phetamine: A potentially neurotoxic amphetamine analogue. Eur J Pharmacol 1986; 124:174–178
   Google Scholar
• Pazos A, Probst A, Palacios JM: Serotonin receptors in the human brain. HI. Autoradiographic mapping of serotonin-1 receptors. Brain Res. 1987; 346:205–230
   Google Scholar
• Moss LE, Neppe VM, Drevets WC: Buspirone in the treat-ment of tardive dyskinesia. J Clin Psychopharmacol 1993; 13:204–208
   PubMed Web of Science ®Google Scholar
• Rickles K, Amsterdam JD, Clary C, et al.: Buspirone in the treatment of depression: A controlled study. J Clin Psychiatry 1991; 52:34–38
   Google Scholar
• Hen R. Boxchert U, Lemeur M, Dierich A, Amara DA, Buhot MC, Segu L, Misslin R, Saudou F: 5:5-HT1B receptor "knockout": Pharmacological and behavioral consequences. Soc Neurosci Abstr 1993; 19:632
   Google Scholar
• Giennon RA: Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 1990; 3: 509–517
   Google Scholar
• Roth BL, Ciar4nello RD, Meltzer HY: Binding of typical and atypical antipsychotic agents with transiently expressed 5-HT1c receptors. J Pharmacol Exp Ther 1992; 260:1361–1365
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee J-C: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251:238–246
   PubMed Web of Science ®Google Scholar
• Garlow S, Morilak D, Dean RS, Roth BL, Ciaranello RD: Production and characterization of an antibody for the 5-HT2 receptor which labels a subpopulation of rat forebrain neu-rons. Brain Res 1993; 615:113–120
   Google Scholar
• Kursar JD, Nelson DL, Wainscott DB, Cohen ML, Baez M: Molecular cloning, functional expression, and pharmacologi-cal characterization of a novel serotonin receptor (5-hy-droxytryptamine2F) from rat stomach fundus. Mol Pharmacol 1992; 42:549–557
   PubMed Web of Science ®Google Scholar
• Tecott LH, Sun L, Julius D: Chimeric mice with targeted dis-ruptions of the 5-HT1c receptor gene. Soc Neurosci Abstr 1993; 19:632
   Google Scholar
• Canton H, Varriele L, Colpaert FC: Binding of typical and atypical antipsychotics to 5-HT1c and 5-HT2 sites: Clozapine potently interacts with 5-HT1c sites. Eur J Pharmacol 1990; 191:93–96
   PubMed Web of Science ®Google Scholar
• Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius DA: Pri-mary structure and functional expression of the 5-HT3 receptor, a serotonin-gated ion channel. Science 1991; 254:432–437
   PubMed Web of Science ®Google Scholar
• CostaII B. Naylor RJ, Tyers MB: The psychopharmacology of 5-HT3 receptors. Pharmacol Ther 1990; 47:181–202
   Google Scholar
• Costal B, Domeney AM, Kelly ME, Naylor RJ, Meltzer HY: 5-HT3 receptor antagonists: Preclinical and clinical consid-erations. In: Racagni G, et al., eds. Biological Psychiatry, Vol I. Amsterdam: Elsevier; 1991: 538–540
   Google Scholar
• Newcomer JW, Faustman WO, Zipursky RB, Csernansky JG: Zacopride in schizophrenia: A single-blind serotonin type 3 antagonist trial. Arch Gen Psychiatry 1992; 49:751–752
   PubMed Web of Science ®Google Scholar
• Bockaert J, Fozard JR, Dumuis A, Clark DE: Trends Phar-macol Sci 1992; 13:141
   PubMed Web of Science ®Google Scholar
• Matthes H, Boschert U, Amlaiky N, Grailhe R, Plassat J-L, Muscatelli F, Mattei M-G, Hen R: Mouse 5-hydroxytryp-tamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: Cloning, functional expression and chromosomal localization. Mol Pharmacol 1993; 43:313–319
   PubMed Web of Science ®Google Scholar
• Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR: Molecular cloning and expression of a 5-HT7 se-rotonin receptor subtype. J Biol Chem 1993; 268:18200–18204
   PubMed Web of Science ®Google Scholar
• Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993; 43:320–327
   PubMed Web of Science ®Google Scholar
• Roth BL, Craigo SC, Choudhary MS, Monsma FJ, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical an-tipsychotic agents to 5-hydroxytryptamine6 (5-HT6) and 5-hy-droxytryptamine7 (5-HT7) receptors. J Pharmacol Exp Ther (in press)
   Google Scholar
• Maes M, Meltzer HY: The role of serotonin in depression. In: Psychopharmacology: A 4th Generation of Progress, 1994 (in press)
   Google Scholar
• Manier DH, Gillespie DD, Sanders-Bush E, Sulser F: The serotonin/noradrenaline-link in brain. I. The role of norad-renaline and serotonin and the regulation of density and function of beta adrenoceptors and its alteration by desipramine. Naunyn Schmiedebergs Arch Pharmacol 1987; 335:109–114
   Google Scholar
• Brunello N, Chuang D-M, Costa E: Different synaptic loca-tion of mianserin and imipramine binding sites. Science 1982; 215:1112–1115
   PubMed Web of Science ®Google Scholar
• Brunello N, Barbaccia ML, Chuang D-M, Costa E: Down-regulation of beta-adrenergic receptors following repeated in-jections of desmethylimipramine: Permissive role of serotonergic neurons. Neuropharmacology 1982; 21:1145–1149
   PubMed Web of Science ®Google Scholar
• Gravel P, deMontigny C: Noradrenergic denervation prevents sensitization of rat forebrain neurons to serotonin by tricyclic antidepressant treatment. Synapse 1987; 1:223–239
   Google Scholar
• Roth BL, Ciaranello RD: Miaserin decreases 5-HT2 radioli-gand binding without altering 5-HT2 receptor mRNA levels. Eur J Pharmacol (Mol Pharmacol) 1991; 207:169–172
   Google Scholar
• Roth BL, Hamblin MW, Ciaranello RD: Regulation of 5-HT2 and 5-HT1c serotonin receptor levels: Methodology and mechanisms. Neuropsychopharmacology 1990; 3:427–433
   Google Scholar
• Hridina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M: 5-HT uptake sites and 5-HT2 receptors in brain of antidepres-sant-free suicide victims/depressives: Increase in 5-HT2 sites in cortex and atrtygdala. Brain Res 1993; 614:37–44
   Google Scholar
• D'haenen H, Bossuyt A, Mertens, J, Bossuyt-Piron C, Gijse-mans M, Kaufman L: SPECT imaging of serotonin2 recep-tors in depression. Psychiatr Res 1992; 45:227–237
   Google Scholar
• Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS: m-Chlorophenylpiperazine (MCPP) effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993; 50: 624–635
   Google Scholar
• Meltzer HY: Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophre-nia. Psychopharmacology 1989; 99:S18—S27
   Google Scholar
• Nyberg S, Farde L, Eriksson L, Halldin C: 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (in press)
   Google Scholar
• Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP: Interaction of antipsychotic drugs with neurotrans-mitter receptor sites in vitro and in vivo in relation to phar-macological and clinical effects: Role of 5HT2 receptors. Psychopharmacology 1993; 112:S40—S54
   Web of Science ®Google Scholar
• Germine M, Goddard AW, Woods SW, Charney DS, Hen-inger GR: Anger and anxiety responses to m-chlo-rophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992; 32:457–461
   Google Scholar
• Strauss WH, Klieser E: Psychotropic effects of ritanserin, a selective S2 antagonist: An open study. Eur Neuropsycho-pharmacol 1991; 1:101–105
   PubMedGoogle Scholar
• Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N: 5-HT2 receptor antagonism in dysthymic disorder: A double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991; 83:244–248
   PubMedGoogle Scholar
• Chouinard G: Sertraline in the treatment of obsessive-com-pulsive disorder: Two double blind, placebo-controlled stud-ies. Int Clin Psychopharmacol 1992; 7:37–41
   PubMed Web of Science ®Google Scholar
• Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L: Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1981; 37:1281–1285
   Google Scholar
• Thoren P, Asberg M. Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L: Clomipramine treatment of obsessive compul- sive disorder. H. Biochemical aspects. Arch Gen Psychiatry 1981; 37:1289–1294
   Google Scholar
• Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ: A double-blind, placebo-controlled study of fluoxetine in patients with DSM-MR obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993; 3:143–152
   PubMedGoogle Scholar
• Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J: A con-trolled trial of fluvoxamine in obsessive-compulsive disorder: Implications for a serotonergic theory. Am J. Psychiatry 1990; 147:1209–1215
   PubMedGoogle Scholar
• Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL: A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to iv mCPP. Biol. Psychiatry 1993; 33:3–14
   PubMed Web of Science ®Google Scholar
• Winchel RM, Jones JS, Stanley B, Molcho A, Stanley M: Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry 1992; 53:304–308
   PubMed Web of Science ®Google Scholar
• Kruesi MI, Fine S, Valladares L, Phillips RA, Rapoport JL: Paraphilias: A double-blind crossover comparison of clomi-pramine versus desipramine. Arch Sex Behav 1992; 21:587–593
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Soloff PH, Perel JM, Ulrich RF: Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26:151–154
   PubMedGoogle Scholar
• Cook EH, Arora RC, Anderson GM, Berry-Kravis EM, Yan SY, Yeoh HC, Sklena PJ, Charak DA, Leventhal BL: Platelet serotonin studies in hyperserotonemic relatives of children with autistic disorder. Life Sci 1993; 52:2005–2015
   PubMed Web of Science ®Google Scholar
• Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50:441–447
   PubMed Web of Science ®Google Scholar
• Realmuto GM, August GJ, Garfinkel BD: Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989; 9:122–125
   PubMed Web of Science ®Google Scholar
• Olivier B, Mos J: Rodent models of aggressive behavior and serotonergic drugs. Prog Neuropsychopharmacol Biol Psy-chiatry 1992; 16:847–870
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides E: Anger attacks in unipolar depression. I. Clinical correlates and response to fluoxetine treatment. Am J Psychiatry 1993; 150:1158–1163
   Google Scholar
• Yudovsky SC, Silver JM, Hales RE: Pharmacologic manage-ment of aggression in the elderly. J Clin Psychiatry 1990; 51(S):22–28
   Google Scholar